HC Wainwright Reiterates Buy on Nektar Therapeutics, $185 Price Target
HC Wainwright & Co. maintained its Buy rating for Nektar Therapeutics stock, setting a price target of $185. This target suggests a potential upside of 293.7% from the previous closing price of $46.99 on Oct. 1. The analyst note highlighted strong data supporting Rezpeg's efficacy.